Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Ipsen SA ADR

Healthcare US IPSEY

42.27USD
-0.932(2.16%)

Last update at 2026-06-03T17:11:00Z

Day Range

42.2742.64
LowHigh

52 Week Range

25.5034.34
LowHigh

Fundamentals

  • Previous Close 43.20
  • Market Cap9641.85M
  • Volume94
  • P/E Ratio21.46
  • Dividend Yield1.13%
  • EBITDA1064.20M
  • Revenue TTM3281.60M
  • Revenue Per Share TTM9.94
  • Gross Profit TTM 2628.70M
  • Diluted EPS TTM1.34

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 706.10M 814.40M 528.60M -38.70000M 494.00M
Minority interest 1.10M -0.10000M 2.70M 2.00M 2.30M
Net income 648.60M 646.60M 548.00M -58.30000M 389.50M
Selling general administrative 205.80M 199.60M 187.80M 181.40M 165.70M
Selling and marketing expenses 833.40M 835.70M 784.00M 838.60M 787.40M
Gross profit 2628.80M 2461.10M 2195.50M 2204.70M 1894.20M
Reconciled depreciation 336.50M 237.00M 234.70M 161.20M 142.60M
Ebit 729.90M 849.50M 719.00M 691.10M 541.20M
Ebitda 1202.30M 1109.30M 953.70M 852.30M 683.80M
Depreciation and amortization 472.40M 259.80M 234.70M 161.20M 142.60M
Non operating income net other - - - - 0.00000M
Operating income 729.90M 849.50M 719.00M 691.10M 519.40M
Other operating expenses 2285.20M 2120.80M 1965.70M 2029.70M 1792.10M
Interest expense 18.50M 23.70M 27.50M 31.40M 10.20M
Tax provision 112.30M 168.20M -17.80000M 19.60M 108.10M
Interest income 0.50M 2.90M 2.30M 2.60M 3.90M
Net interest income -24.00000M -37.30000M 5.40M -0.70000M -24.80000M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 112.30M 168.20M -17.80000M 19.60M 108.10M
Total revenue 3156.50M 2999.10M 2686.10M 2692.70M 2348.40M
Total operating expenses 1757.50M 1582.80M 1475.10M 1541.70M 1337.90M
Cost of revenue 527.70M 538.00M 490.60M 488.00M 454.20M
Total other income expense net -23.80000M -35.10000M -190.40000M -729.80000M -25.40000M
Discontinued operations 55.40M 55.40M 3.80M 4.20M 2.00M
Net income from continuing ops 592.10M 646.70M 545.10M -54.40000M 387.00M
Net income applicable to common shares 648.60M 646.60M 548.00M -50.70000M 389.50M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 5607.90M 5006.80M 4317.20M 4306.90M 3377.40M
Intangible assets 1585.40M 1391.90M 1121.30M 1382.90M 1012.00M
Earning assets - - - - -
Other current assets 239.50M -0.10000M 113.70M -0.10000M 126.40M
Total liab 2271.20M 2252.80M 2195.40M 2553.90M 1534.00M
Total stockholder equity 3337.30M 2751.50M 2119.10M 1751.00M 1841.10M
Deferred long term liab - - - - 0.00000M
Other current liab 684.50M 339.80M 208.90M 244.10M 495.80M
Common stock 83.80M 83.80M 83.80M 83.80M 83.80M
Capital stock 83.80M 83.80M 83.80M 83.80M 83.80M
Retained earnings 648.60M 646.60M 548.00M -50.70000M 389.50M
Other liab 268.80M 252.20M 204.40M 246.70M 574.80M
Good will 579.90M 623.10M 592.90M 632.70M 395.60M
Other assets 327.30M 257.10M 270.10M 181.60M 229.30M
Cash 1169.30M 814.70M 642.50M 353.30M 344.50M
Cash and equivalents - - - - -
Total current liabilities 1335.40M 1228.40M 1213.10M 1452.50M 959.20M
Current deferred revenue - 258.60M 277.30M 414.80M 45.90M
Net debt -501.70000M -121.60000M 228.30M 500.00M -8.90000M
Short term debt 3.80M 35.30M 231.70M 285.10M 37.70M
Short long term debt 3.80M 5.50M 2.80M 285.10M 37.70M
Short long term debt total 667.60M 693.10M 870.80M 853.30M 335.60M
Other stockholder equity 2604.90M 2021.10M 1487.30M 1717.90M 1367.80M
Property plant equipment 581.40M 647.50M 646.60M 679.30M 474.30M
Total current assets 2397.60M 1953.80M 1578.80M 1346.50M 1185.60M
Long term investments - - - 111.40M 173.60M
Net tangible assets 1172.00M 736.30M 417.30M -264.80000M 433.60M
Short term investments 31.00M 42.40M 48.90M 59.30M 5.50M
Net receivables 673.70M 877.40M 559.80M 720.00M 510.70M
Long term debt 581.80M 562.80M 542.70M 568.20M 297.90M
Inventory 284.10M 219.40M 213.90M 214.00M 198.50M
Accounts payable 647.10M 594.70M 495.20M 508.50M 379.80M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - - - - 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 37.20M 46.70M 52.50M 64.00M 9.70M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 3210.30M 3053.00M 2738.40M 2960.40M 2191.80M
Capital lease obligations 109.70M 124.80M 126.30M - 0.00000M
Long term debt total - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -458.60000M -28.40000M -5.90000M -10.60000M -30.20000M
Change to liabilities 29.10M 83.50M 4.50M 98.40M 62.40M
Total cashflows from investing activities -458.60000M -344.20000M -163.70000M -1157.30000M -274.30000M
Net borrowings -34.50000M -280.70000M -184.00000M 643.40M -110.30000M
Total cash from financing activities -164.20000M -401.20000M -307.50000M 550.00M -202.20000M
Change to operating activities 38.50M -15.10000M 3.00M -2.80000M -33.00000M
Net income 592.10M 646.70M 548.90M -50.20000M 389.10M
Change in cash 356.40M 169.50M 300.60M 28.10M 101.60M
Begin period cash flow 809.10M 639.60M 339.00M 310.90M 209.30M
End period cash flow 1165.50M 809.10M 639.60M 339.00M 310.90M
Total cash from operating activities 971.40M 909.20M 771.30M 627.70M 570.90M
Issuance of capital stock 0.00000M 0.00000M 0.00000M 0.10M 2.60M
Depreciation 336.50M 237.00M 234.70M 161.20M 142.60M
Other cashflows from investing activities -76.10000M 96.10M -32.10000M -49.50000M 47.60M
Dividends paid 99.30M 82.90M 83.20M 83.20M 83.00M
Change to inventory -19.90000M -0.50000M -7.10000M -25.60000M -29.80000M
Change to account receivables -86.80000M -67.30000M 56.30M -79.90000M -29.00000M
Sale purchase of stock -11.30000M -36.70000M -36.40000M -16.80000M -10.30000M
Other cashflows from financing activities 1209.70M -0.70000M -3.60000M 650.50M -107.60000M
Change to netincome 139.70M 64.40M 11.80M 481.00M 57.90M
Capital expenditures 252.90M 427.70M 140.70M 280.60M 287.50M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -39.10000M -32.20000M -10.20000M 20.50M -2.90000M
Stock based compensation 26.50M 28.70M 22.50M 15.80M 12.80M
Other non cash items 55.40M -3.60000M -36.30000M -46.00000M -1.10000M
Free cash flow 718.50M 481.50M 630.60M 347.10M 283.40M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IPSEY
Ipsen SA ADR		 -0.932 2.16% 42.27 21.46 11.86 2.88 2.55 2.76 10.19
ZTS
Zoetis Inc		 1.20 1.57% 77.59 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.58 1.91% 31.01 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 153.91 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.79 1.89% 40.92 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Ipsen SA ADR

65 Quai Georges Gorse, Boulogne-Billancourt, France, 92100

Key Executives

Name Title Year Born
Mr. David Loew MD, CEO & Director 1967
Mr. Aymeric Le Chatelier Exec. VP & Group CFO 1969
Dr. Aidan Murphy Ph.D. Exec. VP of Technical Operations 1966
Mr. Craig Marks Vice-Pres of Investor Relations NA
Mr. Francois Garnier Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer 1962
Ms. Gwenan White Exec. VP of Communications & Public Affairs NA
Mr. Regis Mulot Exec. VP & Chief HR Officer 1966
Mr. Stephan Gagne Head of New Tokyo Office NA
Ms. Dominique Bery Head of Nordics & Baltics 1971
Dr. Yan Moore M.D. Sr. VP & Head of Oncology Therapeutic Area 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.